130 Tobey Garden Street
Synchroneuron was founded in 2011 by inventor and neurologist Dr. Barry Fogel, a clinical professor of psychiatry at Harvard Medical School, and the principals of Accellient Partners, a consulting firm that provides outsourced drug development services to established drug companies and “virtual company” services to life sciences startups. The company’s aim is to develop new drugs to meet significant unmet needs for movement disorders by utilizing existing drugs in new ways. Synchroneuron’s reformulation and repurposing strategy offers the potential for a rapid route through clinical trials to regulatory approval.
Synchroneuron secured $6M in Series A financing in 2012 from Morningside Technology Ventures Limited, a leading life science venture capital firm, to advance its lead candidate through a Phase 2 proof of concept trial in patients with TD.